Suppr超能文献

银屑病有效护理的临床目标与障碍

Clinical Goals and Barriers to Effective Psoriasis Care.

作者信息

Strober Bruce E, van der Walt Joelle M, Armstrong April W, Bourcier Marc, Carvalho Andre V E, Chouela Edgardo, Cohen Arnon D, de la Cruz Claudia, Ellis Charles N, Finlay Andrew Y, Gottlieb Alice B, Gudjonsson Johann E, Iversen Lars, Kleyn C Elise, Leonardi Craig L, Lynde Charles W, Ryan Caitriona, Theng Colin T, Valenzuela Fernando, Vender Ronald, Wu Jashin J, Young Helen S, Kimball Alexa B

机构信息

University of Connecticut Health Center, Farmington, CT, USA.

Probity Medical Research, Waterloo, ON, Canada.

出版信息

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

Abstract

Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the treatment goals of psoriasis patients and worldwide barriers to optimal care. Setting clear expectations might ultimately encourage undertreated psoriasis patients to seek care in an era in which great gains in therapeutic efficacy have been achieved. Here, we discuss the option for early treatment of all categories of psoriasis to alleviate disease impact while emphasizing the need for more focused attention for psoriasis patients with mild and moderate forms of this autoimmune disease. In addition, we encourage policy changes to keep pace with the innovative therapies and clinical science and highlight the demand for greater understanding of treatment barriers in resource-poor countries.

摘要

国际银屑病理事会(IPC)邀请了全球主要意见领袖,举行为期一天的圆桌会议,主要目的是讨论银屑病患者的治疗目标以及全球最佳治疗的障碍。明确预期可能最终会鼓励那些治疗不足的银屑病患者在治疗效果取得巨大进展的时代寻求治疗。在此,我们讨论对各类银屑病进行早期治疗以减轻疾病影响的选择,同时强调需要更加关注轻度和中度自身免疫性银屑病患者。此外,我们鼓励政策变革跟上创新疗法和临床科学的步伐,并强调在资源匮乏国家更深入了解治疗障碍的需求。

相似文献

1
Clinical Goals and Barriers to Effective Psoriasis Care.
Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.
2
Definition of treatment goals for moderate to severe psoriasis: a European consensus.
Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21.
4
Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.
5
Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?
Dermatology. 2022;238(2):292-300. doi: 10.1159/000515765. Epub 2021 Jun 9.
6
Treatment goals for moderate to severe psoriasis: an Australian consensus.
Australas J Dermatol. 2013 May;54(2):148-54. doi: 10.1111/ajd.12014. Epub 2013 Jan 18.
8
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
9
Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.
Br J Dermatol. 2001 May;144(5):967-72. doi: 10.1046/j.1365-2133.2001.04183.x.
10
Moderate Psoriasis: A Proposed Definition.
Actas Dermosifiliogr. 2017 Dec;108(10):911-917. doi: 10.1016/j.ad.2017.07.002. Epub 2017 Aug 17.

引用本文的文献

3
The Psychology Behind the Efficacy of a Buddy System for Enhancing Retention in Dermatological Clinical Trials.
Cureus. 2024 Nov 4;16(11):e72986. doi: 10.7759/cureus.72986. eCollection 2024 Nov.
4
Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey.
J Psoriasis Psoriatic Arthritis. 2024 Oct 14:24755303241290495. doi: 10.1177/24755303241290495.
6
Experience of living with psoriasis in Brazil: a Global Psoriasis Atlas online survey.
Int J Dermatol. 2025 Feb;64(2):325-332. doi: 10.1111/ijd.17387. Epub 2024 Jul 17.
7
Granzyme K mediates IL-23-dependent inflammation and keratinocyte proliferation in psoriasis.
Front Immunol. 2024 Jun 5;15:1398120. doi: 10.3389/fimmu.2024.1398120. eCollection 2024.
8
Disease clearance in ulcerative colitis: A new therapeutic target for the future.
World J Gastroenterol. 2024 Apr 7;30(13):1801-1809. doi: 10.3748/wjg.v30.i13.1801.
10
Psoriasis immunometabolism: progress on metabolic biomarkers and targeted therapy.
Front Mol Biosci. 2023 Jun 19;10:1201912. doi: 10.3389/fmolb.2023.1201912. eCollection 2023.

本文引用的文献

1
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections.
J Am Acad Dermatol. 2019 Jan;80(1):43-53. doi: 10.1016/j.jaad.2018.06.056. Epub 2018 Jul 11.
2
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.
J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11.
3
Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165.
4
Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey.
J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2200-2207. doi: 10.1111/jdv.15065. Epub 2018 Jul 31.
5
Treating to Target-A Realistic Goal in Psoriasis?
Semin Cutan Med Surg. 2018 Feb;37(2S):S44-S47. doi: 10.12788/j.sder.2018.010.
6
Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.
Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13.
7
Epidemiology and treatment of psoriasis: a Brazilian perspective.
Psoriasis (Auckl). 2015 Apr 17;5:55-64. doi: 10.2147/PTT.S51725. eCollection 2015.
8
Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians.
J Eur Acad Dermatol Venereol. 2018 Apr;32(4):606-614. doi: 10.1111/jdv.14630. Epub 2017 Nov 6.
10
Psoriasis in Latin America and the Caribbean: a systematic review.
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1991-1998. doi: 10.1111/jdv.14393. Epub 2017 Jul 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验